1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals
Denka Company Limited

Denka Company Limited

4061.T
Denka Company LimitedJP flagTokyo Stock Exchange
4,233.00
JPY
+94.00
- -
364.88BMarket Cap
Denka Company Limited
4061.T
(Tokyo Stock Exchange)

Recent

price

4,233.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
3,645.12
3,737.61
3,585.78
4,029.62
4,186.68
4,078.06
4,097.98
4,496.32
4,720.44
4,404.96
4,109.82
4,463.15
4,726.41
4,516.09
4,644.55
- -
2,342.19
Revenue per Share
146.2
116.11
118.13
145.15
207.39
214.7
205.04
261.79
286.18
262.62
264.23
301.67
148.07
138.6
-142.73
- -
63.77
Basic EPS, GAAP
97.22
62.61
165.09
17.14
83.12
269.92
191.81
266.02
59.44
93.87
36.14
54.23
-358.27
-97.67
-478.2
- -
- -
Free Cash Flow per Basic Share
50.01
50.31
50.2
50.3
50.36
67.69
70.38
85.02
115.2
120.26
125.07
135.07
145.08
90.08
90.09
- -
- -
Dividend per Share
1,130.48
1,202.36
1,235.24
1,353.44
1,483.72
1,646.57
1,816.5
1,889.73
2,075.39
2,242.43
2,387.51
2,552.84
2,555.82
2,605.4
2,368.07
- -
2,651.85
Book Value per Share
1,684.94
1,752.1
1,883.58
2,012.78
2,281.96
2,259.69
2,453.79
2,601.44
2,720.15
2,801.74
2,999.47
3,266.93
3,355.57
3,618.7
3,541.57
- -
3,876.24
Tangible Book Value per Share
98
98
95
94
92
91
88
88
88
86
86
86
86
86
86
86
84
Basic Weighted Avg Shares
357,893
364,712
341,645
376,809
383,978
369,853
362,647
395,629
413,128
380,803
354,391
384,849
407,559
389,263
400,251
- -
197,894
Sales/Revenue/Turnover
6.88
5.68
5.51
5.63
6.26
8.28
7.13
8.51
8.29
8.3
9.8
10.43
7.93
3.44
3.6
- -
1.44
Operating Margin (%)
23,060
24,007
22,463
22,254
23,032
23,241
24,358
24,598
22,945
22,482
22,911
23,882
27,040
26,919
27,857
- -
- -
Depreciation Expense
14,355
11,330
11,255
13,573
19,021
19,472
18,145
23,035
25,046
22,703
22,785
26,012
12,768
11,947
-12,300
- -
5,388
Net Income, GAAP
31.22
35.68
33.81
32.64
28.88
23.54
20.76
21.46
23.03
22.32
24.07
27.92
10.64
17.03
- -
- -
0.2
Effective Tax Rate (%)
4.01
3.11
3.29
3.6
4.95
5.26
5
5.82
6.06
5.96
6.43
6.76
3.13
3.07
-3.07
- -
2.72
Profit Margin (%)
-10,058
-7,039
-12,157
1,102
10,396
14,339
24,712
26,086
36,683
37,645
45,664
51,485
87,336
93,890
39,954
- -
76,427
Working Capital
53,929
49,725
43,156
55,663
53,509
58,510
60,184
51,535
56,969
63,400
78,319
76,016
107,000
110,000
95,000
- -
95,000
LT Debt
168,182
172,736
180,706
189,513
210,796
216,069
227,486
242,779
250,479
254,013
270,036
292,091
300,350
316,913
308,295
- -
332,742
Total Equity
5.89
4.59
4.2
4.66
5.22
6.83
5.93
7.51
7.28
6.46
6.53
6.81
6.35
2.29
- -
- -
0.54
Return on Invested Capital (%)
6.74
5.32
5.04
5.86
7.67
7.55
6.87
8.41
8.94
7.49
7.12
7.84
3.59
3.31
- -
- -
1.43
Return on Capital (%)
13.51
9.92
9.58
11.11
14.48
13.64
11.7
14.09
14.4
12.09
11.4
12.21
5.8
5.37
-5.74
- -
2.4
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
64,368
- -
108,522
LT Borrowings
110,000
- -
95,000
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
86
- -
86
Market Capitalization
202,334
182,797
190,316

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
265,447
- -
279,213
Cash, Cash Equivalents & STI
35,386
- -
38,466
Accounts Receivable, Net
96,431
- -
96,722
Inventories
121,616
- -
131,826
Total Current Liabilities
171,557
- -
202,786
Payables & Accruals
- -
- -
- -
ST Debt
64,368
- -
108,522
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
87,829
103,540
101,474
96,420
389,263
2025
- -
- -
- -
- -
400,251
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
26.62
- -
- -
- -
138.6
2025
- -
- -
- -
- -
-142.73
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
90.08
2025
- -
- -
- -
- -
90.09
2026
- -
- -
- -
- -
- -
Similar Companies
Ningxia Yinglite Chemicals Co., Ltd (000635.SZ)
Benchmark Energy Corporation (BMRK)
DMCC Speciality Chemicals Limited (DMCC.NS)
ResGen Ltd. (RESGEN.BO)
Artius Acquisition Inc. (AACQU)
Amia Co.,Ltd (8438.TW)
Business
Denka Company Limited manufactures and sells a diverse range of organic and inorganic chemicals, electronic materials, pharmaceuticals, and resin-related products primarily in Japan, the rest of Asia, and internationally. The company operates through four main business segments: Electronics & Innovative Products, including acetylene black, functional ceramics, films and tapes, thermally conductive substrates and materials, and adhesives; Life Innovation, encompassing influenza vaccines, antigen testing kits, rapid testing kits for COVID-19, and macromolecular hyaluronate preparations; Elastomers & Infrastructure Solutions, featuring functional elastomers, special cement additives, fertilizers, corrugated pipes such as Toyo Drainpipes, rubber pipe joints, and alumina fiber; and Polymer Solutions, comprising styrene-based performance plastics like DENKA THERMOSHEET sheets (including BOPS, heat-resistant, high heat-resistant, transparent impact-resistant, high-gloss, long life, oil-resistant multilayer, and multicolor variants), acetyl chemicals, synthetic fibers for wigs, food packaging materials, and poval. Founded in 1915 and headquartered in Tokyo, Japan, Denka lists on the Tokyo Stock Exchange Prime Market (ticker: 4061) and employs approximately 6,542 consolidated staff. Recent developments include the launch of Japan's largest polystyrene chemical recycling plant in cooperation with governments to convert used polystyrene into resources; the introduction of the D-NODE brand to promote a circular economy for styrene materials; a strategic investment in a South Korean startup to strengthen its heat-dissipating thermal conductive filler business; completion of investment in a startup developing a wearable electronic stethoscope for digital health advancements; facility reinforcement for production of ALSINK high-reliability heat-dissipating base plates to support power module applications; a strategic investment in Epicore Biosystems alongside Pegasus Tech Ventures in early 2024 to scale personalized hydration wearables in Japan and Asia; suspension of chloroprene rubber production and recording of related extraordinary losses at a U.S. subsidiary; and revision of its Management Plan Mission 2030.